Key TakeawaysCMS’s third drug negotiation cycle under the IRA targets high-expenditure drugs, impacting Medicare Part B and D spending.The list includes drugs for cancer, HIV, and diabetes, with significant financial implications for oncology drugs and Botox.Policy changes, like the Big Beautiful Big Act, exempt orphan drugs from negotiations, affecting drug selection and timelines.The inclusion of […]
